American Journal of Cardiology
Volume 105, Issue 4 , Pages 429-434, 15 February 2010

Relation of Matrix Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 Ratio in Peripheral Circulating CD14+ Monocytes to Progression of Coronary Artery Disease

  • Stefan Brunner, MD

      Affiliations

    • Department of Internal Medicine/Cardiology, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany
    • Corresponding Author InformationCorresponding author: Tel: (+49) 89-7095-6074; fax: (+49) 89-7095-6100
  • ,
  • Jong-Oh Kim

      Affiliations

    • Department of Internal Medicine/Cardiology, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany
  • ,
  • Heiko Methe, MD

      Affiliations

    • Department of Internal Medicine/Cardiology, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany
    • Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts

Received 4 June 2009; received in revised form 7 October 2009; accepted 7 October 2009. published online 07 January 2010.

Atherosclerosis is an inflammatory disease in which systemic inflammation correlates with disease activity. Matrix metalloproteinases (MMPs) contribute to collagen breakdown in atherosclerotic plaques. In the present study, we investigated whether the ratio of MMP-9 and its endogenous inhibitor, tissue inhibitor of metalloproteinase (TIMP)-1, in circulating monocytes correlates with the clinical stages of coronary artery disease. We studied 18 patients with stable angina pectoris (SAP), 14 patients with unstable angina pectoris and non–ST-segment elevation myocardial infarction (UAP/NSTEMI), 14 patients with ST-elevation myocardial infarction (STEMI), and 16 healthy controls. The protein and mRNA levels of MMP-9 and TIMP-1 in CD14+ monocytes were analyzed using real-time polymerase chain reaction and enzyme-linked immunosorbent assay. The activity of serum MMP-9 was assessed using zymography. Compared to the controls (0.07 ± 0.01 relative units) and patients with SAP (0.25 ± 0.1 relative units, p = NS), the monocytic MMP-9 mRNA levels were increased in those with UAP/NSTEMI (0.9 ± 0.3 relative units, p <0.05 vs SAP) or STEMI (1.6 ± 0.4 relative units, p <0.05 vs UAP/NSTEMI). In contrast, the protein and mRNA expression of monocytic TIMP-1 levels was 4.5- to 4.7-fold lower in patients with STEMI than in the controls or those with SAP or UAP/NSTEMI (p <0.05). Changes in monocytic expression of MMP-9 and TIMP-1 tracked with the serum levels of MMP-9 and TIMP-1. The activity of serum MMP-9 correlated with the individual MMP-9/TIMP-1 ratio in the peripheral circulating monocytes (r2 = 0.82, p <0.02). In conclusion, the progression of coronary artery disease was mirrored by an increasing MMP-9/TIMP-1 ratio in the peripheral circulating CD14+ monocytes and serum, respectively. Circulating monocytes displayed the same pattern of imbalance in the expression of MMP-9 and TIMP-1 as previously reported for monocyte-derived macrophages within atherosclerotic plaques, supporting the notion of atherosclerosis as a systemic inflammatory disease.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-9149(09)02518-1

doi:10.1016/j.amjcard.2009.10.013

American Journal of Cardiology
Volume 105, Issue 4 , Pages 429-434, 15 February 2010